Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
UNIVERSITE DE POITIERS manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed between 2 distinct examiners across 2 distinct art units. GULLEDGE, BRIAN M is the busiest examiner for this portfolio, holding 1 pending office action. The distribution of 2 pending office actions across 2 distinct examiners suggests that each matter is being reviewed by a different individual in a different technical group.
The involvement of 2 distinct art units indicates that the university's innovations span different technical sub-fields. This variety requires a prosecution strategy that can adapt to different art unit norms and examiner styles. With 2 distinct examiners involved, the university can observe a range of examiner behaviors, even though BRIAN M GULLEDGE is the only one identified as the busiest with 1 pending office action. This decentralized approach reduces the impact of any single examiner's perspective on the overall portfolio.
Practitioners should note that the Biotechnology & Pharmaceuticals technology area often requires navigating specific biological standards. Having 2 pending office actions across 2 distinct art units provides a broader view of how the USPTO perceives the university's technical disclosures. While the portfolio is currently managed by 2 distinct examiners, the coordination of these matters is essential to maintain consistency. The current data reflects an active engagement across multiple technical groups within the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692318 | VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE | NIEBAUER, RONALD T | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692318 | VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE | NIEBAUER, RONALD T | 1658 | §103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE DE POITIERS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ronald T Niebauer has the most, with 1 of UNIVERSITE DE POITIERS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
